Trial Profile
RTOG 0619: A Randomized Phase II Trial of Chemoradiotherapy versus Chemoradiotherapy and Vandetanib for High Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Therapeutic Use
- 09 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 07 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.